National Heart, Lung, and Blood Institute (NHLBI): Leukemia, Myelogenous, Chronic, BCR-ABL Positive trials
The registry lists 14 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies with National Heart, Lung, and Blood Institute (NHLBI) as lead sponsor. 0 are open to participants now and 7 have results posted.
Phase 1 4Phase 2 10No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)CompletedNCT02208037Phase 2Results posted
- Mismatched Donor Lymphocyte Infusions for Relapsed Disease Following Allogeneic Stem Cell TransplantationCompletedNCT00859586Not applicableResults posted
- Peptide Vaccinations to Treat Patients With Low-Risk Myeloid CancersCompletedNCT00488592Phase 2Results posted
- Stem Cell Transplantation for Patients With Cancers of the BloodCompletedNCT00467961Phase 2Results posted
- Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic MalignancyCompletedNCT00433745Phase 2Results posted
- Methods to Enhance the Safety and Effectiveness of Stem Cell TransplantsCompletedNCT00378534Phase 2Results posted
- Specialized Blood Cell Transplants for Cancers of the Blood and Bone MarrowCompletedNCT00003838Phase 2Results posted
- Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral InfectionsTerminatedNCT02231853Phase 1
- Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell TransplantationCompletedNCT02226861Phase 1
- Improving Blood Stem Cell Collection and Transplant ProceduresCompletedNCT01517035Phase 1/2
- Natural Killer Cells and Bortezomib to Treat CancerCompletedNCT00720785Phase 1
- Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous LeukemiaCompletedNCT00079313Phase 2
- Experimental Bone Marrow Transplant ProtocolCompletedNCT00061581Phase 2
- Modified Bone Marrow Stem Cell Transplantation for Chronic Myelogenous LeukemiaCompletedNCT00001144Phase 2